SEQIRUS UK LIMITED
Location
Founded
2015-05-29
Website
Risk Signals
39 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Offices of Holding Companies, Not Elsewhere Classified, Business Services, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SEQIRUS UK LIMITED
Live alerts from global media, monitored by Business Radar
2025-03-31 (miragenews.com)
Flu Cases Surge, Vaccines Now Available |
To date, there have been over 46,300 lab-confirmed influenza cases in Australia, more than 50% higher than the previous record of flu cases in
Read more2025-03-19 (pharmaphorum.com)
4th Circular & Self-Amplifying RNA Therapeutics Summit |
With CSL Seqirus and Arcturus Therapeutics successfully developing the first approved self-amplifying RNA vaccine, the field of next generation RNAs celebrates the potential of circular and self-amplifying RNAs to provide improved stability, durability, longevity and efficacy for treating a wide array of diseases.
Read more
2025-03-17 (businesswire.com)
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of inf...
Read more2025-03-07 (biospace.com)
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress -
Phase 2 interim data for ARCT-032 (CF) & ARCT-810 (OTCD) on track for Q2 2025
Read more2025-01-15 (genengnews.com)
Maritime History Holds the Key to a Vaccine Manufacturing Powerhouse
The historical role of the British city of Liverpool as a trading port has helped it to become a center of excellence for vaccine manufacturing.
Read more2024-12-11 (thetimes.com)
Innovation takes centre stage at Pharma Industry Awards UK 2024 - The Times & The Sunday Times
The Health & Safety award was presented to CSL Seqirus. Nige Hilton, VP Manufacturing and Site Head, Liverpool, commented: “The Pharma Industry Awards are a fantastic opportunity to recognise people, teams and organisations for the tremendous contributions they are making to this critically important sector.”
Read more2024-12-04 (openaccessgovernment.org)
UK government strengthen their pandemic preparedness with H5 influenza vaccine
In the possible event of a pandemic, the UK has secured 5 million doses of an H5 influenza vaccine to stay one step ahead of the avian influenza virus
Read more2024-12-03 (thepeoplesvoice.tv)
UK Govt Buys Millions Of Doses Of New Bird Flu Vaccine Amid Pandemic Fears
The British Government has secured a contract for more than five million doses of the human H5 influenza vaccine, in, what they claim, is an effort to bolster the country’s defences against a potential pandemic. [...]
Read more2024-10-30 (stocktitan.net)
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
Amarin reports mixed Q3 results: 36% revenue decline to $42.3M, but maintains $306M cash position. European VAZKEPA sales surge 19% while U.S. sales face headwinds. See detailed analysis of pharma giant's performance.
Read more2024-07-16 (telegraph.co.uk)
The Liverpool vaccine factory preparing for a H5N1 bird flu pandemic
Researchers at the vast facility describe the ‘pre-pandemic’ jabs being made there as a ‘first line of defence’
Read more2024-06-24 (agriland.ie)
Ireland to receive vaccines for people at higher risk of bird flu
Ireland is due to receive doses of a vaccine for people deemed to be at a higher risk of exposure to bird flu in the coming months.
Read more2024-06-21 (thecattlesite.com)
Weekly global protein digest - China, HPAI in poultry and cattle, Finland to offer avian flu vaccines to high-risk workers
Analyst Jim Wyckoff reports on global protein news
Read more